Mylan expands oncology portfolio with launch of generic tarceva tablets
Mylan N.V. recently announced the U.S. launch of erlotinib hydrochloride tablets, 25 mg, 100 mg and 150 mg, a generic version of Genentech’s Tarceva. Mylan Pharmaceuticals received final approval from the U.S.